

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Results from the I-SPY 2 trial demonstrated that the addition of pembrolizumab to neoadjuvant chemotherapy improved the pathologic complete response rate for which population of patients?
 - a. Those with TNBC
 - b. Those with hormone receptor-positive breast cancer
 - c. Both a and b
2. What is the usual recommended dose of talazoparib for patients with HER2-negative advanced breast cancer and germline BRCA mutations?
 - a. One capsule once daily
 - b. One capsule twice daily
 - c. Two capsules twice daily
3. The OlympiAD trial comparing olaparib to treatment of physician's choice for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation demonstrated which overall survival outcome with olaparib in the overall population?
 - a. A statistically significant improvement
 - b. No statistically significant improvement
4. What is the most common toxicity of concern associated with talazoparib?
 - a. Diarrhea
 - b. Headache
 - c. Anemia
5. The risk of recurrence for patients with TNBC is typically at its highest how many years after primary treatment?
 - a. Three or less
 - b. Three to 5
 - c. More than 5
6. The Phase III IMpassion130 study demonstrated a significant improvement in overall survival with *nab* paclitaxel and atezolizumab compared to *nab* paclitaxel and placebo for which population of patients with metastatic TNBC?
 - a. Intent-to-treat population
 - b. Patients with PD-L1-positive tumors
 - c. Both a and b
7. The Phase III ASCENT trial is evaluating which antibody-drug conjugate for patients with relapsed/refractory TNBC?
 - a. Sacituzumab govitecan
 - b. Ladiratuzumab vedotin
 - c. Trastuzumab deruxtecan
8. Which is the more likely site of first recurrence in patients with TNBC?
 - a. Visceral organs or brain
 - b. Bone
9. Which outcome best describes the comparative pathologic complete response rate with the addition of veliparib to carboplatin/paclitaxel in the BrighTNess trial for TNBC?
 - a. A statistically significant improvement
 - b. No statistically significant improvement
10. The Phase II GeparNuevo trial investigated which checkpoint inhibitor in combination with anthracycline/taxane-based neoadjuvant therapy for localized TNBC?
 - a. Pembrolizumab
 - b. Nivolumab
 - c. Durvalumab